Trials / Recruiting
RecruitingNCT05183074
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
Phase II Prospective Trial of MR-linac Based Stereotactic Ablative Radiotherapy for Patients With Localized (SAMRT-P01) and Oligo-metastatic (SMART-P02) Prostate Cancer
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
1. To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer 2. To assess the acute and late toxicities, efficacy and quality of life for patients treated by MRL-SBRT 3. To simulate the dose planning and assess the feasibility of simultaneous-boost for MR-prominent foci 4. To investigate the relationship between the changes of blood and tissue biomarkers and manifestations on mp-MRI pre-/post-MRL-SBRT, to further ascertain the predictive factors of local persisting and/or relapse disease
Conditions
- Prostate Cancer
- Radiotherapy Side Effect
- Magnetic Resonance-linac
- Stereotactic Ablative RT
- Adaptive Radiotherapy
- Localised Disease
- Oligometastatic Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MR-linac | 1.5-Tesla MR-linac based SBRT |
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2022-01-10
- Last updated
- 2025-12-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05183074. Inclusion in this directory is not an endorsement.